Literature DB >> 2960733

Reduced receptor binding by a human interferon-gamma fragment lacking 11 carboxyl-terminal amino acids.

P O Leinikki1, J Calderon, M H Luquette, R D Schreiber.   

Abstract

Treatment of recombinant human interferon-gamma (IFN-gamma) with either 1) the arginine-specific proteases clostripain or submaxillaris protease or 2) the broadly specific enzyme pronase produced a stable fragment with m.w. of 15,500. Structural analysis showed that the cleavage occurred between residues 129 and 130 and thus produced a fragment lacking only 11 carboxyl-terminal amino acids. The fragmented and untreated molecules showed identical amino-terminal amino acid sequences and were equally reactive with either polyclonal or monoclonal anti-IFN-gamma. IFN-gamma lacking carboxyl-terminal amino acids displayed a 1000- to 2000-fold reduction in its capacity to bind to cellular IFN-gamma receptors at 4 degrees C. Functionally the fragment showed a 50-fold reduction in its ability to induce antiviral activity in fibroblasts and a 10-fold reduction in its ability to induce Fc receptors on the human histiocytic lymphoma cell line U937. These results thus suggest that the carboxyl terminus of human IFN-gamma contributes significantly to the formation of the receptor-binding site of the molecule.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960733

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Interaction of truncated human interferon gamma variants with the interferon gamma receptor: crucial importance of Arg-129.

Authors:  J Haelewyn; L Michiels; P Verhaert; M F Hoylaerts; R Witters; M De Ley
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

2.  Normal human intestinal B lymphocytes. Increased activation compared with peripheral blood.

Authors:  M G Peters; H Secrist; K R Anders; G S Nash; S R Rich; R P MacDermott
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

3.  Proteolytic inactivation of cytokines by Pseudomonas aeruginosa.

Authors:  M Parmely; A Gale; M Clabaugh; R Horvat; W W Zhou
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

4.  Modulation of major histocompatibility complex protein expression by human gamma interferon mediated by cysteine proteinase-adhesin polyproteins of Porphyromonas gingivalis.

Authors:  P L Yun; A A DeCarlo; N Hunter
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

Review 5.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Authors:  Elise Alspach; Danielle M Lussier; Robert D Schreiber
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-03-01       Impact factor: 10.005

6.  A development-specific protein in Myxococcus xanthus is associated with the extracellular fibrils.

Authors:  D L Clemans; C M Chance; M Dworkin
Journal:  J Bacteriol       Date:  1991-11       Impact factor: 3.490

7.  ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus.

Authors:  Anna Osiak; Olaf Utermöhlen; Sandra Niendorf; Ivan Horak; Klaus-Peter Knobeloch
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

8.  Modulation of an interleukin-12 and gamma interferon synergistic feedback regulatory cycle of T-cell and monocyte cocultures by Porphyromonas gingivalis lipopolysaccharide in the absence or presence of cysteine proteinases.

Authors:  Peter L W Yun; Arthur A DeCarlo; Charles Collyer; Neil Hunter
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Pseudomonas aeruginosa alkaline protease degrades human gamma interferon and inhibits its bioactivity.

Authors:  R T Horvat; M J Parmely
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

10.  Molecular organization of the interferon gamma-binding domain in heparan sulphate.

Authors:  H Lortat-Jacob; J E Turnbull; J A Grimaud
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.